TY  - GEN
AU  - Garcia-Albeniz, Xabier
AU  - Alonso, Vicente
AU  - Escudero, Pilar
AU  - Mendez, Miguel
AU  - Gallego, Javier
AU  - Rodriguez, Jose Ramón
AU  - Salud, Antonia
AU  - Fernandez-Plana, Julen
AU  - Manzano, Hermini
AU  - Zanui, Montserrat
AU  - Falcó, Esther
AU  - Feliu, Jaime
AU  - Gil, Mireia
AU  - Fernandez-Martos, Carlos
AU  - Bohn, Uriel
AU  - Alonso, Carmen
AU  - Calderero, Veronica
AU  - Rojo, Federico
AU  - Cuatrecasas, Miriam
AU  - Maurel, Joan
PY  - 2019
DO  - 10.1634/theoncologist.2018-0728
SN  - 1083-7159
UR  - https://hdl.handle.net/20.500.12105/22832
AB  - Background: RAS testing is used to select patients with anti-epidermal growth factor receptor (EGFR) therapies sensitivity in metastatic colorectal cancer (mCRC). However, other biomarkers such as BRAF, PIK3CA/PTEN, and p-IGF-1R+/MMP7+ (double...
LA  - eng
PB  - Wiley
KW  - Colorectal cancer
KW  - Biomarkers
KW  - Cetuximab
KW  - Clinical score
KW  - Aged
KW  - Humans
KW  - ErbB Receptors
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Progression-Free Survival
KW  - Middle Aged
KW  - Cetuximab
KW  - Antineoplastic Agents, Immunological
KW  - Prognosis
KW  - Male
KW  - Prospective Studies
KW  - Mutation
KW  - Biomarkers, Tumor
KW  - Female
KW  - Colorectal Neoplasms
KW  - Drug Resistance, Neoplasm
KW  - ras Proteins
TI  - Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02)
TY  - research article
ER  -